Zomedica Pharmaceuticals Corp - Asset Resilience Ratio

Latest as of March 2025: 38.30%

Zomedica Pharmaceuticals Corp (ZOM) has an Asset Resilience Ratio of 38.30% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ZOM liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

$54.77 Million
Cash + Short-term Investments

Total Assets

$142.99 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Zomedica Pharmaceuticals Corp's Asset Resilience Ratio has changed over time. See ZOM net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Zomedica Pharmaceuticals Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ZOM stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $54.77 Million 38.3%
Total Liquid Assets $54.77 Million 38.30%

Asset Resilience Insights

  • Very High Liquidity: Zomedica Pharmaceuticals Corp maintains exceptional liquid asset reserves at 38.30% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Zomedica Pharmaceuticals Corp Industry Peers by Asset Resilience Ratio

Compare Zomedica Pharmaceuticals Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
Lucid Diagnostics Inc
NASDAQ:LUCD
Medical Devices 6.09%
Business Alignment Public Company Limited
BK:BIZ
Medical Devices 0.63%
Somnomed Ltd
AU:SOM
Medical Devices 24.67%
T&R Biofab Co. Ltd
KQ:246710
Medical Devices 0.12%
Cleanspace Holdings Ltd
AU:CSX
Medical Devices 29.39%
Curvebeam Ai Ltd
AU:CVB
Medical Devices 8.27%
Cochlear Ltd
AU:COH
Medical Devices 9.76%

Annual Asset Resilience Ratio for Zomedica Pharmaceuticals Corp (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Zomedica Pharmaceuticals Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 31.02% $64.33 Million $207.36 Million +0.40pp
2023-12-31 30.63% $77.55 Million $253.20 Million -10.54pp
2022-12-31 41.16% $115.09 Million $279.61 Million -28.37pp
2021-12-31 69.53% $194.95 Million $280.40 Million -24.20pp
2020-12-31 93.72% $61.99 Million $66.14 Million +56.82pp
2019-12-31 36.91% $1.54 Million $4.18 Million -16.09pp
2018-12-31 53.00% $3.20 Million $6.03 Million -24.04pp
2017-12-31 77.04% $4.02 Million $5.22 Million +10.86pp
2016-12-31 66.18% $3.23 Million $4.88 Million --
2015-12-31 0.00% $0.00 $3.86 Million --
pp = percentage points

About Zomedica Pharmaceuticals Corp

NYSE MKT:ZOM USA Medical Devices
Market Cap
$53.90 Million
Market Cap Rank
#21714 Global
#4712 in USA
Share Price
$0.06
Change (1 day)
+0.00%
52-Week Range
$0.06 - $0.06
All Time High
$2.98
About

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more